"Never doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has."

Margaret Mead
Case report
peer-reviewed

A Case Report of Fructosamine’s Unreliability as a Glycemic Control Assessment Tool in Nephrotic Syndrome



Abstract

Fructosamine (FA) is a glycated primary amine widely used as an alternative method for the assessment of glycemic control when glycosylated hemoglobin (HbA1c) measurement is unreliable or if there is a need for short-term glycemic control monitoring. We report a case of a 36-year-old male patient with a six-year history of poorly controlled type 2 diabetes mellitus and nephrotic syndrome. As the nephrotic syndrome progressed, we observed a decline in his serum FA levels that did not correlate with his increased HbA1c due to significant albuminuria. This case report highlights the unreliability of FA in patients with nephrotic syndrome and the significance of other glycemic markers.



Want to read more?

Create a free account to continue reading this article.

Already a member? Login.



Case report
peer-reviewed

A Case Report of Fructosamine’s Unreliability as a Glycemic Control Assessment Tool in Nephrotic Syndrome


Author Information

Sri HarshaVardhan Senapathi

Internal Medicine, Mount Sinai Icahn School of Medicine Queens Hospital New York

Ravi Bhavsar Corresponding Author

Internal Medicine, Mount Sinai Icahn School of Medicine Queens Hospital New York

Regina Kaur

Internal Medicine, Mount Sinai Icahn School of Medicine Queens Hospital New York

Paul Kim

Internal Medicine, Mount Sinai Icahn School of Medicine Queens Hospital New York

Issac Sachmechi

Internal Medicine, Mount Sinai Icahn School of Medicine Queens Hospital New York


Ethics Statement and Conflict of Interest Disclosures

Human subjects: Consent was obtained by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.


Case report
peer-reviewed

A Case Report of Fructosamine’s Unreliability as a Glycemic Control Assessment Tool in Nephrotic Syndrome


Figures etc.

Share
Case report
peer-reviewed

A Case Report of Fructosamine’s Unreliability as a Glycemic Control Assessment Tool in Nephrotic Syndrome

Sri HarshaVardhan Senapathi">Sri HarshaVardhan Senapathi, Ravi Bhavsar">Ravi Bhavsar , Regina Kaur">Regina Kaur, Paul Kim">Paul Kim, Issac Sachmechi">Issac Sachmechi

  • Author Information
    Sri HarshaVardhan Senapathi

    Internal Medicine, Mount Sinai Icahn School of Medicine Queens Hospital New York

    Ravi Bhavsar Corresponding Author

    Internal Medicine, Mount Sinai Icahn School of Medicine Queens Hospital New York

    Regina Kaur

    Internal Medicine, Mount Sinai Icahn School of Medicine Queens Hospital New York

    Paul Kim

    Internal Medicine, Mount Sinai Icahn School of Medicine Queens Hospital New York

    Issac Sachmechi

    Internal Medicine, Mount Sinai Icahn School of Medicine Queens Hospital New York


    Ethics Statement and Conflict of Interest Disclosures

    Human subjects: Consent was obtained by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

    Acknowledgements


    Article Information

    Published: September 16, 2017

    DOI

    10.7759/cureus.1694

    Cite this article as:

    Senapathi S, Bhavsar R, Kaur R, et al. (September 16, 2017) A Case Report of Fructosamine’s Unreliability as a Glycemic Control Assessment Tool in Nephrotic Syndrome. Cureus 9(9): e1694. doi:10.7759/cureus.1694

    Publication history

    Received by Cureus: August 21, 2017
    Peer review began: September 12, 2017
    Peer review concluded: September 13, 2017
    Published: September 16, 2017

    Copyright

    © Copyright 2017
    Senapathi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 3.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

    License

    This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Fructosamine (FA) is a glycated primary amine widely used as an alternative method for the assessment of glycemic control when glycosylated hemoglobin (HbA1c) measurement is unreliable or if there is a need for short-term glycemic control monitoring. We report a case of a 36-year-old male patient with a six-year history of poorly controlled type 2 diabetes mellitus and nephrotic syndrome. As the nephrotic syndrome progressed, we observed a decline in his serum FA levels that did not correlate with his increased HbA1c due to significant albuminuria. This case report highlights the unreliability of FA in patients with nephrotic syndrome and the significance of other glycemic markers.



Want to read more?

Create a free account to continue reading this article.

Already a member? Login.



Sri HarshaVardhan Senapathi

Internal Medicine, Mount Sinai Icahn School of Medicine Queens Hospital New York

Ravi Bhavsar, M.D.

Internal Medicine, Mount Sinai Icahn School of Medicine Queens Hospital New York

For correspondence:
ravi_bhavsar@outlook.com

Regina Kaur

Internal Medicine, Mount Sinai Icahn School of Medicine Queens Hospital New York

Paul Kim

Internal Medicine, Mount Sinai Icahn School of Medicine Queens Hospital New York

Issac Sachmechi

Internal Medicine, Mount Sinai Icahn School of Medicine Queens Hospital New York

Sri HarshaVardhan Senapathi

Internal Medicine, Mount Sinai Icahn School of Medicine Queens Hospital New York

Ravi Bhavsar, M.D.

Internal Medicine, Mount Sinai Icahn School of Medicine Queens Hospital New York

For correspondence:
ravi_bhavsar@outlook.com

Regina Kaur

Internal Medicine, Mount Sinai Icahn School of Medicine Queens Hospital New York

Paul Kim

Internal Medicine, Mount Sinai Icahn School of Medicine Queens Hospital New York

Issac Sachmechi

Internal Medicine, Mount Sinai Icahn School of Medicine Queens Hospital New York